Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors

Vanessa F. Merino1, Soonweng Cho1, Xiaohui Liang1, Sunju Park1, Kideok Jin1, Qian Chen2, Duojia Pan2, Cynthia A. Zahnow1, Alan R. Rein3 and Saraswati Sukumar1

1 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 HIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD, USA

Keywords
breast; IGF; mutation; PIK3CA; STAT3

Correspondence
S. Sukumar, Breast and Ovarian Cancer Program, CRB1/143, 1650 Orleans Street, Baltimore, MD 21231, USA
Tel: +1 410 614 2479
E-mail: saras@jhmi.edu
and
V. F. Merino, Breast and Ovarian Cancer Program, CRB1/136, 1650 Orleans Street, Baltimore, MD 21231, USA
Tel: +1 410 614 4075
E-mail: vmerino1@jhmi.edu

(Received 17 September 2016, revised 2 February 2017, accepted 28 February 2017, available online 6 April 2017)
doi:10.1002/1878-0261.12053

1. Introduction

The phosphatidylinositol 3-kinase (PI3K) pathway is a key regulator of growth, survival, and metabolism in both normal and malignant cells (Zhao and Vogt, 2008). Over 70% of breast cancers show activation of the PI3K pathway through mechanisms such as HER2 amplification, deletion of the tumor suppressor PTEN, or oncogenic mutations in PIK3CA (Zhao and Vogt, 2008). The PIK3CA gene encodes the catalytic subunit p110α, and its amplification and/or mutation is associated with several types of solid tumors (Bachman et al., 2004; Kadota et al., 2009; Samuels et al., 2004; Wu et al., 2005). Activating somatic mutations in PIK3CA

Abbreviations
muPIK3CA, mutant PIK3CA; PI3Ki, PI3K inhibitor; PIK3CA, phosphoinositide 3-kinase catalytic subunit.
are present in ~30% of human breast cancers of all stages (Bachman et al., 2004; Barbareschi et al., 2007; Miller, 2012; Saal et al., 2005). In 47% of these cases, mutations occur in the kinase domain, most frequently the H1047R substitution in exon 20. In 33% of these cases, mutations occur in the helical domain; here, the most frequent ones are the E545K and E542K substitutions in exon 9 (Bachman et al., 2004; Bader et al., 2005). PIK3CA mutations cause a gain of enzymatic function, stimulate AKT signaling, induce growth factor, and anchorage independent growth in culture (Bader et al., 2005; Ikenoue et al., 2005; Isakoff et al., 2005). Expression of H1047R-mutant PIK3CA in the mammary gland induces tumors in transgenic mice (Adams et al., 2011; Meyer et al., 2011; Tikoo et al., 2012; Yuan et al., 2013). Therefore, inhibition of PI3K represents a potentially attractive strategy for the treatment of breast cancer. In fact, a number of PI3K inhibitors (PI3Ki) have entered clinical trials (Zardavas et al., 2011; Papadopoulos et al., 2014). Laboratory studies and early clinical trials indicate that several of the PI3Ki demonstrate preferential inhibition of tumors with PIK3CA mutations (Mayer et al., 2017; O’Brien et al., 2010). However, while long-term stabilization and partial tumor responses are observed in PIK3CA-positive breast cancers treated with PI3Ki (NCT01219699) (Brana and Siu, 2012), the majority of mutant cancers do not experience substantial regression (Bendell et al., 2012). Strategies to overcome both de novo and adaptive resistance to PI3Ki have employed combination therapy. Combined inhibition of PI3K and mammalian target of rapamycin complex (mTORC) is associated with stable disease in phase 1 clinical trials (Markman et al., 2012; Papadopoulos et al., 2014). In addition, clinical trials using a combination of PI3Ki with fulvestrant, IGF-1R antibody (AMG479), or lapatinib have been initiated (Zardavas et al., 2014).

This study sought to characterize the molecular mechanisms of action of mutant p110α in tumors derived from genetically engineered mouse models to further define targets for treating PIK3CA-driven tumors and their metastatic progression, with the goal of developing mechanism-based combination therapies.

2. Materials and methods

2.1. Cell lines and reagents

The HS578T cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). Low passages of the cell line were used to avoid loss of fidelity to the original cells. Stable cell lines were derived from PIK3CA-H1047R mouse mammary tumors. Cell lines derived from recurrent H1047R mouse tumors (RDR-C234 and RDR-A677) were kindly provided by Jean Zhao from Dana-Farber Cancer Institute (Liu et al., 2011). Sources of other reagents were as follows: XAV939 (Tocris, Minneapolis, MN, USA); S31-201 (SelleckChem, Houston, TX, USA); linsitinib, OSI-906 (LC Labs, Woburn, MA, USA); LY294002 (Sigma-Aldrich, St. Louis, MO, USA), and GDC-0941 (Genentech, San Francisco, CA, USA). Neu-N (c-erbB2, ERBB2, Her-2) mice were derived from the colony of Guy et al. (1992), bred to homozygosity as verified by Southern blot analysis (Reilly et al., 2000), and maintained at Johns Hopkins University.

2.2. Site-directed mutagenesis and cloning of human PIK3CA-mutant transgenes into MKbpAll vector

The plasmid containing the PIK3CA-mutant H1047R and E545K sequences were generated by the use of site-directed mutagenesis kit (Quick Change; Stratagene, La Jolla, CA, USA). Automated design of mutagenic primers for site-directed mutagenesis was performed by primerex (Bioinformatics.org).

Primers used were as follows: H1047R forward: 5′-C AAATGAATGATGCACGTGTCGTAAGAGATCTGGAC-3′, reverse: 5′-GTCGAAGCCACCATGACGTGCATCATT CATTG-3′; E545K forward: 5′-CTCTCTGAAATCT ACTAACAGAGAGAAAGATT TTC-3′, reverse: 5′-G AAAATTTTCTCTGCTTAGTGATTTCAGAGAG-3′.

Mammary gland-specific expression of PIK3CA was driven using wild-type or E545K- or H1047R PIK3CA-mutant genes cloned into the MKbpAll vector containing the mouse mammary tumor virus MMTV-LTR promoter/enhancer and KCR intron to increase transgene expression (gift from Jeffrey Rosen, Baylor College of Medicine).

2.3. HS578T-PIK3CA-mutant cell lines

HS578T breast cancer cells were stably transfected with pcDNA3.1-PIK3CA-mutant plasmids (H1047R or E545K) using FuGENE 6 (Roche Molecular Systems, Branchburg, NJ, USA) according to the manufacturer’s instructions. Successfully transfected cells were selected in culture medium containing 700 μg·mL⁻¹ G418 (ThermoFisher Scientific, Waltham, MA, USA) for 4 weeks before the clones were isolated. The clones were pooled and maintained in complete medium containing 400 μg·mL⁻¹ of G418.

2.4. Generation, handling, and genotyping of transgenic mice

All animal studies were performed following approval of the Institutional Animal Care and Use Committee.
of the Johns Hopkins School of Medicine. Transgenic mice were generated by microinjecting the 9.4-kb fragment of pMMTV-PIK3CA into the pronucleus of single-cell embryos isolated from superovulated FVB/N mice by the Transgenic Mouse Core Facility at National Cancer Institute. The transgenic founders from the different PIK3CA-mutant strains were transferred to Johns Hopkins animal facility. The transgenic F1 generation was crossed with FVB/N mice and the progeny maintained as hemizygous for the PIK3CA-mutant allele. The genotype of transgenic mice was assessed in tail clip DNA by PCR using MMTV and PIK3CA-specific primers (forward primer, 5'-CTGGTCATCATCCTGCTTT-3'; reverse primer, 5'-CCTCACCGAGGCATTCTAAA-3'). The presence of the respective PIK3CA mutations in the transgenic mouse DNA was confirmed by sequencing.

2.5. Determination of transgene copy number and expression

Southern blot analysis and real-time quantitative PCR (D'Haene et al., 2010) were employed to determine the transgene copy number inserted into the founder genome. Briefly, mouse genomic DNA was digested with Bam H1, hybridized with the E545K or H1047R PIK3CA probes, and the membranes were developed using the Odyssey reagent (Licor Biosciences, Lincoln, NE, USA), according to the manufacturer’s instructions. For gene expression, real-time quantitative PCR was conducted using the Maxima SYBR Green/ROX Master Mix (Fermentas, Waltham, MA, USA) per the manufacturer protocol as previously described (Merino et al., 2016). Primer sequences will be provided upon request.

2.6. Immunohistochemistry (IHC) of mouse tumors

The rabbit antiphosphorylated STAT3 primary antibody (#9131; Cell Signaling, Beverly, MA, USA) was used at 1 : 100 dilution and IHC performed as described (Merino et al., 2016).

2.7. Histology

5-μm thick sections of FFPE mouse tumor fragments were stained with hematoxylin and eosin (H&E) and assessed by the pathologist blinded to group of origin.

2.8. Whole-mount analysis

The number 4 (inguinal) mammary glands were dissected, fixed overnight in Carnoy’s solution (3 : 1, 95% ethanol and glacial acetic acid), and stained with carmine alum as previously described (Gu et al., 2009).

2.9. Cell proliferation assay

5 × 10^3 cells per well were plated in 96-well plates in triplicate and treated with the indicated drugs, alone and in combination. After 48 h, cell proliferation assay was performed as previously described (Merino et al., 2016).

2.10. Western blot analysis

Western blotting was performed as previously described (Merino et al., 2016) using antibodies to phosphorylated AKT-Ser (#4058S), phosphorylated GSK3-β (#9323P), and phosphorylated STAT3 (#9131) from Cell Signaling, Danvers, MA, USA; activated β-catenin (#05665), STAT3 (#06596), and GAPDH (#MAB374) from Millipore, Billerica, MA, USA; β-catenin (#138400) and cyclin D1 (#AHF0102) from ThermoFisher Scientific.

2.11. Flow cytometry

Single cells were isolated from mammary gland and tumors (Shackleton et al., 2006) and stained with CD24-PE (clone M1/69), 7AAD (BD Pharmingen, San Diego, CA, USA), and CD49f-APC (clone GoH3; RD Systems). Samples were run on the BD FACS Calibur system (Becton Dickinson, San Antonio, TX, USA), and data were analyzed using FLOWJO software (FlowJo LLC, Ashland, OR, USA).

2.12. Analysis of TCGA data

The processed RNA-seq dataset and clinical information of the The Cancer Genome Atlas (TCGA) breast carcinoma (BRCA) database hosted on the Firehose server managed by the Broad Institute (Center, 2015) were used for analysis of correlations of gene expression with disease subtype. PIK3CA mutation and HER2 amplification information was obtained from the cBioPortal interactive analysis platform (Gao et al., 2013). Single sample gene set analysis (ssGSEA) (Barbie et al., 2009) implemented by the GSVA package (Hanzelmann et al., 2013) was used to estimate activation scores of PIK3CA-related pathways curated by the Molecular Signatures Database (Liberzon et al., 2011). Pairwise Welch’s corrected t-test with Bonferroni correction for multiple testing was used to calculate significance in differences across groups.
2.13. Statistical analysis

mRNA expression, assessed by Q-PCR, was expressed as mean ± standard errors of mean. Mann–Whitney U-test was performed to assess median of mRNA and protein levels for tumors. Student’s t-test was performed to compare cell viability, mRNA, and protein levels in cell lines and expressed as the mean (± SEM). Statistical significance was defined as $P < 0.05$ and calculated using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA).

3. Results

3.1. Generation of transgenic mice with mammary gland-specific overexpression of PIK3CA-H1047R- and -E545K-mutant genes

To examine the role of PIK3CA-H1047R and -E545K mutations during mammary development and their ability to induce mammary tumors, we generated transgenic mice with expression of the PIK3CA-mutant genes under the control of the mammary epithelial-specific MMTV promoter (Fig. 1A). The presence of mutant PIK3CA in the transgenic mouse DNA was confirmed by sequencing. Southern blot analysis (Fig. S1A) and quantitative PCR (Fig. S1B) were employed to determine copy numbers of the transgene inserted into the founder genome. As PIK3CA mutations occur on single alleles in the genome, we selected the founders that had a small number of transgene insertions in their genome. In comparison with FVB/N control mice, levels of PIK3CA mRNA (Fig. S1C), protein (Fig. S1D), as well as its downstream effector protein phosphorylated Akt-Ser (Fig. S1D), were found to be higher in the mammary glands of pregnant transgenic mice. These findings are as predicted because the MMTV promoter is hormonally regulated and is activated in mammary gland during pregnancy and peaks at lactation (Wagner et al., 2001).

3.2. Mutants of PIK3CA increase side branching, delay involution, and induce tumorigenesis

To examine the effects of PIK3CA mutations on mammary gland development, we performed whole-mount staining analysis of mammary glands from newly generated PIK3CA-H1047R and -E545K low copy number transgenic mice at different stages of mammary gland development (virgin, pregnancy, and involution). At 8 weeks, the ductal tree of the PIK3CA-H1047R and -E545K transgenic mice had a significantly greater level of branching in comparison with control FVB/N mice (Fig. 1B). On day 13 of pregnancy, there were no significant phenotypic differences in the morphology of the mammary gland among these mice, except a slight increase in branching observed in the H1047R mutants (Fig. S1E). At day 29 of involution, most of the alveolar structures of FVB/N and PIK3CA-E545K mammary glands collapsed into clusters of epithelial cells and more adipocytes filled the spaces (Fig. 1C). On the other hand, PIK3CA-H1047R mice showed delayed involution and the alveolar structures were largely intact and filled with milk (Fig. 1C). Using Wnt knockout mice, Brisken et al. (2000) showed that Wnt proteins function as paracrine factors that operate downstream of progesterone and the progesterone receptor to mediate the process of side branching (Brennan and Brown, 2004). As we observed altered side branching in the mammary glands of PIK3CA-mutant mice, we investigated whether the Wnt/β-catenin pathway is induced in the PIK3CA-H1047R- and PIK3CA-E545K-mutant mammary glands. We found that mammary glands of PIK3CA-mutant mice showed an increase in activated β-catenin (Fig. S1F) and its downstream gene, cyclin D1 (Fig. S1D).

Parous mice with low copy number of PIK3CA-H1047R and -E545K alleles were observed for 2 years to determine whether H1047R and -E545K transgenes initiate mammary tumorigenesis. In the PIK3CA-H1047R strain, tumors arose in 12 (30%) of 40, and in PIK3CA-E545K strain, tumors arose in 4 (13%) of 30 aged female mice. Tumors were carcinomas with tubular, papillary, and comedo features (Fig. 1D). As previously reported in PIK3CA-H1047R-knock-in mouse models (Tikoo et al., 2012; Yuan et al., 2013), these tumors arose with long latency (> 12 months). No tumors were observed in the aging wild-type female FVB/N littermates. PIK3CA-H1047R tumors expressed estrogen receptor (ER) alpha at levels similar to ER-positive breast cancer cell lines (Fig. S1G).

3.3. Wnt/β-catenin pathway is activated in PIK3CA-H1047R-mutant tumors

Higher levels of β-catenin expression in the normal glands of PIK3CA-mutant mice (Fig. S1F), and reports that PIK3CA-H1047R caused an expansion of the luminal progenitor population (Tikoo et al., 2012), led us to hypothesize that the Wnt signaling pathway is likely to be activated in the PIK3CA-H1047R human breast tumors. We also compared signaling responses between Her2- and PIK3CA-H1047R mouse tumors.

Although PI3K is downstream of Her-2 signaling, we saw many differences between mammary tumors.
arising in transgenic mice overexpressing Her-2 versus PIK3CA-H1047R, reflecting differences observed between wild-type and mutant PI3K. PIK3CA-H1047R mammary tumors showed strong activation of phosphorylated AKT, phosphorylated Gsk3-β, cyclin D1, and activated β-catenin compared to tumors from Her-2 transgenic mice (Fig. 2A). The mRNA expression levels of Axin 2, a transcriptional target of the Wnt/β-catenin pathway (Jho et al., 2002), were higher in PIK3CA-H1047R-mutant tumors compared to Her-2 tumors (Fig. 2B). Axin 2 was also induced in tumor cells derived from recurrent tumors (RDR-C234 and RDR-A677) from the H1047R-doxycycline-inducible mouse model (Liu et al., 2011) (Fig. 2B). Consistent with predicted consequences of activation of the Wnt/β-catenin pathway, single cells isolated from PIK3CA-H1047R tumors contained a larger CD24med/CD49fhi stem cell population (63%) compared to normal mammary glands (12% at 2 months and 20% at pregnancy) (Fig. S2). Although it was
reported that PIK3CA-H1047R caused an expansion of the luminal progenitor population (Tikoo et al., 2012), we did not observe a difference in the CD24med/CD49fhi stem cell population between FVBN and PIK3CA-H1047R mammary glands.

To extend these findings in mouse mammary tumors to human tumor cells, we overexpressed PIK3CA-H1047R- and PIK3CA-E545K-mutant genes in the human breast cancer cell line, HS578T. Human breast cancer cells expressing mutant PIK3CA also showed activation of the WNT/β-catenin pathway, which was detected as an increase in activated β-catenin (ABC) protein (Fig. 2C), the ligand WNT3A mRNA (Fig. 2D, left panel), and a decrease in mRNA expression of the negative modulator of the pathway, the secreted frizzled-related protein 1 (sFRP-1) (Fig. 2D, right panel).

### 3.4. STAT3 is activated in PIK3CA-H1047R tumors

An IL-6-STAT3 loop was shown to mediate resistance to PI3K inhibitors by inducing epithelial-mesenchymal...
transition (EMT) and cancer stem cell expansion in human breast cancer cells (Yang et al., 2014). Therefore, we investigated whether Il6-Stat3 signaling is induced in H1047R-mouse tumors and could be utilized as a therapeutic target in combination with PI3K inhibitors.

Phosphorylated Stat3 expression was higher in the mouse mammary tumors from PIK3CA-H1047R mice in comparison with tumors from Her-2/neo transgenic mice, as determined by IHC (Fig. 3A,B) and western blot analysis (Fig. 3C). Upstream of Stat3, Il6 tended to be highly expressed (Fig. 3D) and hepatocyte growth factor (Hgf) is significantly highly expressed (Fig. 3E) in mammary tumors arising in PIK3CA-H1047R in comparison with Her-2 transgenic mice.

Fig. 3. Stat3 is activated in PIK3CA-H1047R tumors. (A) Immunohistochemistry analysis and (B) Student’s t-test quantification of phosphorylated Stat3 protein in PIK3CA and Her-2 tumors. (C) Western blot (left panel) and Mann–Whitney U-test quantification (right panel) of phosphorylated-Stat3 and Stat3 in PIK3CA-H1047R and Her-2 tumors. Gapdh: loading control. Quantitative RT-PCR of (D) interleukin 6 (Il6) and (E) hepatocyte growth factor (Hgf) expression in PIK3CA-H1047R (PIK3CA-HR)-mutant and Her-2 tumors. RPL19 was used as a housekeeping gene. The mean (± SEM) of mRNA in each tumor in triplicate is shown. Mann–Whitney U-test was performed, and the median of mRNA levels for all tumors is shown on the right. *P < 0.05; **P < 0.01; ***P < 0.001.
3.5. Insulin-like growth factor (IGF) is activated in PIK3CA-H1047R tumors

The activation of insulin-like growth factor 1 receptor (Igf-1R) and downstream PI3K pathway has been implicated in resistance to PI3K inhibitors (Leroy et al., 2016). Although there was no difference in Igf-1 mRNA levels (Fig. 4A, a), Igf-2 mRNA was significantly higher in PIK3CA-H1047R mammary tumors in comparison with Her-2 tumors (Fig. 4A, b). PIK3CA-H1047R tumors also showed higher mRNA levels of Igf-1R (Fig. 4B, a) and lower levels of Igf-2R (Fig. 4B, b) in comparison with Her-2 tumors. Igf-1R protein levels tended to be higher in PIK3CA-H1047R tumors in comparison with Her-2 tumors (Fig. 4C). HS578T human breast cancer cell lines overexpressing the H1047R showed threefold, and E545K mutants showed fivefold higher IGF-1R levels than the parental HS578T cells (Fig. 4D).
3.6. PIK3CA-mutant tumor cells are targeted by anti-Wnt, anti-STAT3, and anti-IGF-1R drugs in combination with PI3K inhibitors

We assembled a panel of cell lines from our PIK3CA-H1047R mouse mammary tumors, generated human HS578T-H1047R and -E545K breast cancer cell lines, and obtained cell lines derived from recurrent H1047R mouse tumors (RDR-C234 and RDR-A677) (Liu et al., 2011). We evaluated their sensitivity to inhibitors of Wnt/β-catenin (XAV939), STAT3 (S31-201), and IGF-1R (OSI-906) alone, or in combination with the PI3K inhibitor, LY294002.

Treatment of PIK3CA-H1047R mouse tumor cells and RDR-C234 with XAV939 (1, 5, and 10 μM) or S31-201 (3, 15, and 30 μM) alone had no effect on cytotoxicity (Fig. S3), while the cells were sensitive to the combination of PI3K and STAT3 inhibitors (Fig. 5A a, b). RDR-C234 cells were also sensitive to PI3Ki in combination with Wnt/β-catenin inhibitors (Fig. 5A, b).

There was no increase in the cytotoxic effect of the combination therapies in comparison with PI3K inhibition alone on parental HS-578T breast cancer cells (Fig. 5B, a). In contrast, HS578T cells that overexpressed PIK3CA-H1047R responded more efficiently to combinations of PI3K and STAT3 inhibitors.

![Graphs](image.png)

**Fig. 5.** PIK3CA-mutant tumor cells are targeted with Wnt, STAT3, and IGF-1R drugs in combination with PI3K inhibitors. Cell growth inhibition upon treatment for 48 h with the PI3Ki, LY294002 alone or in combination with an inhibitor of β-catenin, XAV939 (X, 5 μM), or STAT3, S31-201 (S, 30 μM). P values (* of L+S and (#) of L+X, in relation to LY294002. (A) Mammary tumor cell lines from (a) H1047R- MMTV transgenic (PIK-HR-216, -225, -228, -724) and (b) doxycycline-inducible H1047R (RDR-C234) mice. (B) Human breast cancer cell line (a) HS578T or (b) HS578T-H1047R cells. (C) Two PIK3CA-H1047R tumor cell lines derived from doxycycline-inducible H1047R mouse tumors (RDR-A677 and RDR-C234) were treated (a) for 48 h with the PI3K inhibitors LY294002 (2.5 and 5 μM) alone and (b) GDC-0941 (G, 0.05, 0.1, and 1 μM) alone, or in combination with an inhibitor of IGF-1R, OSI-906 (O, 50 and 100 nM). P values (* of L+O or G+O (O, 50 nM) and (#) of L+O or G+O (O, 100 nM), in relation to LY294002 or GDC-0941, are shown. Student’s t-test was performed, and the mean (± SEM) of the quadruplicate is shown. *P < 0.05; **P < 0.01; ***P < 0.001.
compared to single agents (Fig. 5B, b). Similar to cell lines derived from our PIK3CA-H1047R transgenic mice tumors (Fig. 5A, a) the combination of PI3K and Wnt/β-catenin inhibitors did not improve the cytotoxicity achieved by the PI3Ki alone (Fig. 5B, b). These results suggest that combination of PI3Ki with STAT3 inhibitor is more effective than combination of PI3Ki with the Wnt/β-catenin inhibitor. In addition, H1047R mouse tumor cells, RDR-C234 and RDR-A677, derived from recurrent tumors, responded more efficiently to a combination of inhibitors of PI3K (both LY294002 and GDC-0941) and IGF-1R (OSI-906) in comparison with single treatments (Fig. 5C). These results with mouse and human cells containing the PIK3CA hotspot mutation H1047R suggest that targeting specific pathways that are additionally activated in these tumors potentiates the killing effect of PI3Ki and may overcome drug resistance.

3.7. STAT3, β-catenin, and IGF pathways are induced in human PIK3CA tumors

We next evaluated whether the pathways activated in the mutated PIK3CA mouse tumors involved in the cell killing effect in combination with the PI3Ki are also regulated in luminal human tumors containing the PIK3CA hotspot mutations. Analysis of 965 primary breast tumors from TCGA RNA-seq dataset showed that breast tumors harboring H1047R and other PIK3CA mutations (including E545K and E542K) have significant upregulation of AXIN2, HGF, STAT3, IGF-1, and IGF-2 mRNA compared with PIK3CA-wild-type and HER-2-amplified tumors (Fig. 6A). Estimated using the ssGSEA (single sample gene set analysis) method (Barbie et al., 2009), PIK3CA-mutant breast tumors showed activated AKT, IGF1-mTOR, and WNT canonical signaling pathways compared to PIK3CA-wild-type and HER2-overexpressing tumors (Fig. 6B).

Thus, our comprehensive molecular analysis of PIK3CA-H1047R mouse and in silico analysis of human tumors revealed activation of Wnt/β-catenin, STAT3, and IGF-1R pathways. Therefore, combined targeting of pathways altered in PIK3CA-mutant tumors offers the potential to improve treatment regimens with PI3K inhibitors.

4. Discussion

PIK3CA, the gene encoding the catalytic subunit p110α of PI3K, is an excellent target for therapy. Since their discovery, PI3K inhibitors have been developed but have experienced limited success in the clinic. One of the underlying reasons is the possible reliance of the tumors on activated compensatory pathways occurring upon PI3K blockade. To decipher other pathways that are activated in PIK3CA-mutant tumors and with a goal of developing improved treatment regimens for mutant tumors, we generated transgenic mouse models with mammary gland-specific overexpression of the PIK3CA hot spot mutations, H1047R and E545K. We have identified key alternate pathways active in mutant tumors and have demonstrated effective therapy regimens that use combinations of PI3K-i and other pathway-specific drugs.

Characterization of the transgenic models showed that mutant mice have increased mammary ductal branching compared to control FVB/N, and H1047R mutants displayed delayed involution (Fig. 1B,C). Mouse models of PIK3CA-H1047R transgenic mice showed abnormalities in mammary gland development such as an increase in mammary ductal side branching (Adams et al., 2011; Tikoo et al., 2012). Further, transgenic mice with alteration in PI3K pathway, such as AKT activation (Schwertfeger et al., 2001), PIK3CA membrane localization (Renner et al., 2008), and PIK3CA-H1047R (Meyer et al., 2011), showed delayed involution, attributed to a reduced number of apoptotic cells. Transgenic mice with loss of PTEN exhibited excessive ductal branching, delayed involution, and severely reduced apoptosis (Jho et al., 2002). In PIK3CA-mutant mice generated by us, we observed that the PIK3CA-mutant glands have an increase in activated β-catenin and the downstream cyclin D1. The phenotypes observed in the PIK3CA-mutant mice were in line with the known role of Wnt signaling in ductal branching (Brennan and Brown, 2004). We observed mammary tumors at the lower end of the frequencies (range 25–100%) as reported by others in the PIK3CA-H1047R mice (Adams et al., 2011; Meyer et al., 2011; Tikoo et al., 2012; Yuan et al., 2013). Tumor incidence was possibly proportional to the expression levels of the mutant protein. We also generated PIK3CA-E545K transgenic mice. Here again, the incidence was low – 4 (13%) of 30 PIK3CA-E545K female mice developed mammary tumors. As previously reported in PIK3CA-H1047R-knock-in mouse models (Tikoo et al., 2012; Yuan et al., 2013) and PIK3CA-E545K (Meyer et al., 2011), we observed that PIK3CA-H1047R and -E545K tumors arose with long latency (> 12 months) (Fig. 1D). It was previously reported that expression of PIK3CA-mutant H1047R induces heterogeneous tumors (Meyer et al., 2011), an observation in line with our own findings of differing histologies in the PIK3CA-H1047 tumors.
of PIK3CA-mutant E545K in the mouse mammary gland was also shown to induce heterogeneous tumors although it is less potently tumorigenic compared to mutant H1047R (Meyer et al., 2013). Also, similar to others (Koren and Bentires-Alj, 2013), we observed that PIK3CA-H1047R tumors are ER alpha positive (Fig. S1G).

Following molecular characterization of PIK3CA-H1047R tumors, we identified different pathways induced in the mutant tumors in comparison with tumors which have an activated, but wild-type PI3K pathway, such as mammary tumors from the MMTV-Her2 mice. The Wnt/β-catenin (Fig. 2) and Stat3 (Fig. 3) pathways were activated in PIK3CA-H1047R tumors. The β-catenin and IGF pathways are induced in human PIK3CA tumors. (A) Expression of mutated PIK3CA-related genes in 965 primary luminal breast tumors using The Cancer Genome Atlas (Center) RNA-seq dataset. (B) Pathway score estimation of mutated PIK3CA-related signaling pathways in the same tumor set using the ssGSEA (single sample gene set analysis) method. PIK3CA-H1047R (HR, n = 125), other PIK3CA mutants (Mut, n = 188), including E545K and E542K, Her2 (n = 118), and non-PIK3CA-mutant (wild-type, wt, n = 534) breast tumors. Pairwise Welch’s corrected t-test with Bonferroni correction for multiple testing was used. *P < 0.05; **P < 0.01; ***P < 0.001.
breast tumors and human breast cancer cell line overexpressing mutant PIK3CA. Consistent with this finding, gene expression profiling of PIK3CA-mutant, ERα-positive breast cancer revealed activation of the Wnt and Jak/STAT signaling pathway (Cizkova et al., 2010). In addition, PTEN deletion and PI3K activation were shown to cooperate with Wnt1 to induce mammary tumors (Li et al., 2004). Combinations of PI3K/mTOR and JAK2/STAT5 inhibitors effectively target triple-negative breast cancer (Britschgi et al., 2012). Stat3 signaling was shown to be required for PI3K-mediated transformation of mouse fibroblast (Hart et al., 2011). An IL-6-STAT3 loop was shown to mediate resistance to PI3K inhibitors by inducing EMT and cancer stem cell expansion in human breast cancer cells (Yang et al., 2014). In fact, Ile6 and Hgf (Fig. 3D,E), activators of Stat3, and the stem cell population (Fig. S2) were induced in PIK3CA-H1047R tumors. Recently, it was described that PIK3CA-H1047R induces multipotency and multilineage mammary tumors (Koren et al., 2015; Van Keymeulen et al., 2015).

Another interesting observation was that the expression of insulin-like growth factor 2 (Igf2) and Igf-1R was significantly higher, while expression of Igf-2R, which degrades IGF-2 (Brown et al., 2009), was lower in H1047R tumors (Fig. 4). This finding is consistent with previous observations that Igf-2R promoted endocytosis and lysosomal degradation of Igf-2, thereby antagonizing its action and acting as a tumor suppressor protein (Brown et al., 2009). These findings are also in accordance with previous reports, which showed that activation of PI3K pathway, through reduction in PTEN in breast tumor cells, is associated with increased proliferation in response to IGF-2 (Church et al., 2012). In addition, a correlation between IGF-1R and downstream PI3K pathway activation was reported in drug resistance (Fox et al., 2011; Gallardo et al., 2012; Leroy et al., 2016), and IGF-1R and PI3K dual treatments act synergistically in targeting breast cancer cells (Ayub et al., 2015).

Here, we have demonstrated that the use of specific inhibitors to the pathways which we identified as induced in PIK3CA-mutant tumors, such as STAT3, β-catenin, and Igf-1R, potentiates the cytotoxic effect of PI3K inhibitor on mutant PI3CA tumor cells (Fig. 5). In addition, we showed that H1047R and other PIK3CA mutants, including E545K and E542K containing BRCA2, have significant upregulation of several genes/pathways identified in the mouse PIK3CA-mutant tumors, when compared to human PIK3CA-wild-type and HER-2-positive tumors (Fig. 6), suggesting the translational potential of our findings in this paper using model systems.

5. Conclusions

In summary, by generating transgenic mice expressing two hotspot mutants of PIK3CA in the mammary glands and through detailed characterization of their tumors, we have identified activation of Wnt/β-catenin, Stat3, and Igf-1R pathways. We have shown that the combined targeting of these additional pathways altered in PIK3CA-mutant tumors may improve the success of treatment regimens that include PI3K inhibitors (Fig. S4).

Acknowledgements

We thank Lionel Feigenbaum of the Transgenic Mouse Core Facility at National Cancer Institute for generation of the PIK3CA-mutant lineage founders and Dr. David Huso for the analysis of tumor histology. We also thank Dr. Jeffrey Rosen from Baylor College of Medicine for providing us with the MKbpAII plasmid and Dr. Jean Zhao from Dana-Farber Cancer Institute for kindly providing the mouse cell lines RDR-C234 and RDR-A677. This work was funded by the DOD BCRP Center of Excellence Grant W81XWH-04-1-0595 and Komen Scholar Grant to SS, and DOD BCRP Postdoctoral Fellowship, W81XWH-09-1-0499 to VM.

Author contributions

VM, SC, XL, and SS were responsible for the conception and experimental design. VM, SC, XL, SP, KJ, QC, and CZ performed the experiments. VM, SC, XL, DP, AR, and SS acquired the data. VM, SC, XL, DP, AR, CZ, and SS conducted analysis and interpretation of data. VM, SC, and SS wrote and revised the manuscript. SS was responsible for study supervision.

References

Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, Wang W, Wright KL, Lane TF, Zacksenhaus E et al. (2011) Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 71, 2706–2717.

Ayub A, Yip WK and Seow HF (2015) Dual treatments targeting Igf-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line. Biomed Pharmacother 75, 40–50.

Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3, 772–775.
Bader AG, Kang S, Zhao L and Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5, 921–929.

Barbareschi M, Buttitta F, Felicioni L, Cotrapi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E and Marchetti A (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13, 6064–6069.

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Myelans E, Scholl C et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108–112.

Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M et al. (2012) Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30, 282–290.

Brana I and Siu LL (2012) Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 10, 161.

Brennan KR and Brown AM (2004) Wnt proteins in mammary development and cancer. J Mammary Gland Biol Neoplasia 9, 119–131.

Brisker C, Heineman A, Chavarria T, Elenbaas B, Tan J, Dey SK, McMahon JA, McMahon AP and Weinberg RA (2000) Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev 14, 650–654.

Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet C, Muller U, Murakami M, Radimerski T and Bentires-Alj M (2012) JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22, 796–811.

Broad Institute TCGA Genome Data Analysis Center (2015) Analysis-ready standardized TCGA data from Broad GDAC Firehose coadata_2015_04_02 run.

Brown J, Jones EY and Forbes BE (2009) Keeping IGF-II under control: lessons from the IGF-II-IGF2R crystal structure. Trends Biochem Sci 34, 612–619.

Church DN, Phillips BR, Stuecky DJ, Barnes DJ, Bufla FM, Manek S, Clarke K, Harris AL, Carter EJ and Hassan AB (2012) Igf2 ligand dependency of Pten(±) developmental and tumour phenotypes in the mouse. Oncogene 31, 3635–3646.

Cizkova M, Cizeron-Clairac G, Vacher S, Susini A, Andrieu C, Lidereau R and Bieche I (2010) Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway. PLoS One 5, e15647.

D’Haene B, Vandesompele J and Hellemans J (2010) Accurate and objective copy number profiling using real-time quantitative PCR. Methods 50, 262–270.

Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, Liu S, Gonzalez-Angulo AM, Mills GB, Ye F et al. (2011) A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71, 6773–6784.

Gallardo A, Lerma E, Escuin D, Tibau A, Munoz J, Ojeda B, Barnadas A, Adrover E, Sanchez-Tejada L, Giner D et al. (2012) Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related to trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106, 1367–1373.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1.

Gu B, Sun P, Yuan Y, Moraes RC, Li A, Teng A, Agrawal A, Rheume C, Bilanchone V, Veltmaat JM et al. (2009) Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol 185, 811–826.

Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ (1992) Expression of the new protooncogene in the mammary epithelium of transgenic mice induces metastasic disease. Proc Natl Acad Sci U S A 89, 10578–10582.

Hanzelmann S, Castelo R and Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7.

Hart JR, Liao L, Yates JR III and Vogt PK (2011) Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A 108, 13247–13252.

Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65, 4562–4567.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearlree RV, Cantley LC and Brugge JS (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65, 10992–11000.

Jho EH, Zhang T, Domon C, Joo CK, Freund JN and Costantini F (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22, 1172–1183.

Kadota M, Sato M, Duncan B, Ooshima A, Yang HH, Diaz-Meyer N, Gere S, Kageyama S, Fukuoka J, Nagata T et al. (2009) Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 69, 7357–7365.

Koren S and Bentires-Alj M (2013) Mouse models of PIK3CA mutations: one mutation initiates...
heterogeneous mammary tumors. *FEBS J* **280**, 2758–2765.

Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O et al. (2015) PIK3CA (H1047R) induces multipotency and multi-lineage mammmary tumours. *Nature* **525**, 114–118.

Leroy C, Ramos P, Cornille K, Benenfant D, Fritsch C, Voshol H and Bentires-Alj M (2016) Activation of IGFlR/p110beta/AKT/mTOR confers resistance to alpha-specific PI3K inhibition. *Breast Cancer Res* **18**, 41.

Li Y, Podosypanina K, Liu X, Crane A, Tan LK, Parsons R and Varmus HE (2001) Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. *BMC Mol Biol* **2**, 2.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P and Mesirov JP (2011) Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739–1740.

Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA et al. (2011) Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. *Nat Med* **17**, 1116–1120.

Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuerdo M, Stutvoet S, Birle D et al. (2012) Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. *Ann Oncol* **23**, 2399–2408.

Mayer IA, Abramson V, Formisano L, Balko JM, Estrada MV, Sanders M, Juric D, Solit D, Berger MF, Won H et al. (2017) A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+/HER2-negative metastatic breast cancer. *Clin Cancer Res* **23**, 26–34.

Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YM, Zhou XC, Zhang Z et al. (2016) Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. *Cancer Res* **76**, 2013–2024.

Meyer DS, Brinkhaus H, Muller U, Muller M, Cardiff RD and Bentires-Alj M (2011) Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. *Cancer Res* **71**, 4344–4351.

Meyer DS, Koren S, Leroy C, Brinkhaus H, Muller U, Klebba I, Muller M, Cardiff RD and Bentires-Alj M (2013) Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. *Oncogenesis* **2**, e74.

Miller TW (2012) Initiating breast cancer by PIK3CA mutation. *Breast Cancer Res* **14**, 301.

O’Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC et al. (2010) Predictive biomarkers of sensitivity to the phosphatidylinositol 3’ kinase inhibitor GDC-0941 in breast cancer preclinical models. *Clin Cancer Res* **16**, 3670–3683.

Papadopoulos KP, Tabernerio J, Markman B, Patnaik A, Tolcher AW, Baselga J, Shi W, Egile C, Ruiz-Soto R, Laird AD et al. (2014) Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. *Clin Cancer Res* **20**, 2445–2456.

Reilly RT, Gottlieb MB, Ercolini AM, Mchills JP, Kane CE, Okoye FI, Muller WJ, Dixon KH and Jaffee EM (2000) HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. *Cancer Res* **60**, 3569–3576.

Renner O, Blanco-Aparicio C, Grassow M, Canamero M, Leaf JF and Carnero A (2008) Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. *Cancer Res* **68**, 9643–9653.

Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrpm PO, Mansukhani M, Enoksson J et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* **65**, 2554–2559.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. *Science* **304**, 554.

Schwrtfeger KL, Richert MM and Anderson SM (2001) Mammary gland involution is delayed by activated Akt in transgenic mice. *Mol Endocrinol* **15**, 867–881.

Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ and Visvader JE (2006) Generation of a functional mammary gland from a single stem cell. *Nature* **439**, 84–88.

Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Hambert P and Phillips WA (2012) Physiological levels of Pik3ca (H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERAlpha-positive tumors. *PLoS One* **7**, e36924.

Van Keymeulen A, Lee MY, Ousset M, Brohee S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I et al. (2015) Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. *Nature* **525**, 119–123.
Wagner KU, McAllister K, Ward T, Davis B, Wiseman R and Hennighausen L (2001) Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. 

Transgenic Res 10, 545–553.

Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S et al. (2005) Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7, R609–R616.

Yang L, Han S and Sun Y (2014) An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells. Biochem Biophys Res Commun 453, 582–587.

Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M et al. (2013) Conditional activation of Pik3ca (H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32, 318–326.

Zardavas D, Phillips WA and Loi S (2014) PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 16, 201.

Zhao L and Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27, 5486–5496.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article:

Fig. S1. Determination of PIK3CA mutant transgene copy number and expression, and characterization of mutant normal mammary gland.

Fig. S2. Stem cell population in PIK3CA-H1047R normal mammary glands and tumors.

Fig. S3. PIK3CA mutant tumor cells are targeted with Wnt, STAT3 and IGF-1R drugs in combination with PI3K inhibitors.

Fig. S4. Schematic representation of signaling pathways activated in PIK3CA mutant breast tumor cells.